Eisana Health is an early-stage medical device company founded in The Woodlands, Texas in 2020 by Dr. Carole Spangler Vaughn. The company focuses on developing products to prevent side effects from cancer treatments, starting with peripheral neuropathy—a common and painful result of common chemotherapy drugs.
About Eisana Health
Our Technology
As the Eisana Health cooling system offers a novel approach to CIPN management by providing a safe and non-invasive cooling solution, it has the advantage of being a device-based intervention with a very low risk of any side effects, making it a highly attractive option for both patients and healthcare providers.
Our Founder's Story
Dr. Carole Spangler Vaughn, CEO and founder, has a PhD in Biophysics and an MBA. She has spent over 25 years in the life science industry, mostly working for startups, bringing novel Oncology products to market.
In 2017, she was diagnosed with Stage 2b breast cancer which means it had already advanced to her lymph nodes. While she knew about the evidence-based treatment protocols and knew she would survive, she was surprised to learn about all the side effects. She did not know that all cancer survivors are left with at least one long term problem. There are a lot of people suffering in silence. She was even more surprised to learn that some of the most devastating side effects can be prevented.
She discovered that something as simple as cooling could prevent one of the most common side effects from chemotherapy, nerve damage in hands and feet (peripheral neuropathy), and assumed there would be good patient-centric solutions available to her. Unfortunately, she discovered the solutions were far from ideal. It was hard for her to reconcile using baggies of frozen corn to keep her hands and feet cold on the day of chemotherapy, at a global leader in cancer care.
Because no reasonable solution exists to this significant problem, she decided to solve the problem and founded Eisana Health because unnecessary pain and suffering should never be the price of survival.
Our Team
Our team includes a robust combination of experts across medical, financial, and commercial strategy. The company is also guided by a group of expert advisors in fields such as medical devices, clinical research, regulatory, oncology, neurology, intellectual property, and business strategy, ensuring that Eisana Health's products are well-positioned for both clinical success and market adoption.
Eisana Health Leadership Team
Dr. Carole Spangler
Founder & CEO. Dr. Vaughn holds a Ph.D. in BioPhysics (Johns Hopkins University) and an MBA (University of Washington). She has spend over 25 years in the life science industry, mostly at start-ups, bringing oncology products to market.
Jessica Urban
VP, Product Development, Quality & Regulatory. Jessica Urban has over 25 years of experience in medical device product development, including roles in management, business development, program management, quality, regulatory, and engineering.
Paul Klein
VP, Marketing. Paul Klein spent over 40 years at GE and GE Healthcare in various positions globally. He is an experienced marketer with B2B and B2C expertise in durables, CPG, and medical products.
Nathan Dale
VP, Engineering. Nathan Dale is a medical device engineer with nearly 30 years of expertise in product design, development, and manufacturing across implantable, disposable, and surgical technologies.
Martin Simonetti
Board Chair. Martin Simonetter has had a long and successflu career in the life sciences, serving as CFO and CEO. He is currently the CEO of PBS Biotech. He received an MS from the University of California, Davis and an MBA from the University of Santa Clara.
Rob Meyers, JD
Legal & Business Advisor. Ron Myers has braod experience in M&A, licensing, litigation, and intellectual property. He has more than 20 years experience in intellectual property acquisition, enforcement, and defenses in biotech and pharmaceutical fields.
Dr. Noah Kolb
Medical Advisor. Dr. Noah Kolb is a neurologist at The University of Vermont Medical Center and assistant professor at the UVM College of Medicine Department of Neurology in Burlington, VT. His research focuses on chemotherapy-induced neuropathy.
Jennifer Gewandter, PhD, MPH
Medical Advisor. Jennifer Gewandter is an assistant professor in the Department of Anesthesiology and Perioperative Medicine at the University of Rochester and an Associate Director of the FDA Public-Private partnership, ACTTION. Her research is focused on optimizing clinical trials for pain and peripheral neuropathy treatments as well as researching interventions for chemotherapy-induced peripheral neuropathy.
Dr. Hope Rugo
Medical Advisor. Hope Rugo, M.D., is division chief of breast medical oncology and professor at City of Hope, directing the Women's Cancers Program and leading national research initiatives. A globally recognized authority in breast cancer and clinical trial design, she has helped establish new standards of care while advancing toxicity-reducing innovations such as scalp cooling. Her 500+ publications, ASCO leadership, and international awards reflect a career dedicated to expanding access to patient-centered cancer care worldwide.
Dr Carole Spangler Vaughn
Behind every innovation is a reason to fight. For Carole, it has always been for her family.